LYEL
HealthcareLyell Immunopharma, Inc.
$28.01
$-0.97 (-3.35%)
Jan 5, 2026
Price History (1Y)
Analysis
Lyell Immunopharma, Inc. is a biotechnology company operating within the healthcare sector. With a market capitalization of $595.04 million and approximately 300 employees, it maintains a moderate scale in its industry. The company's financial health reveals significant challenges. Lyell Immunopharma reported a net income loss of $325,660,000 in the trailing twelve months, accompanied by an EBITDA of -$184,380,992. The operating margin is notably poor at -248353.3%, and the profit margin is 0.0%. Returns on equity (ROE) and assets (ROA) are also negative, standing at -75.8% and -24.2%, respectively. Notably, the company has a substantial amount of cash, totaling $319.62 million, but it also has a considerable debt load of $44.28 million. Lyell Immunopharma's valuation context is marked by a forward P/E ratio of -33.35 and a price to sales ratio of 14513.25. Revenue growth was negative at -55.9% year-over-year. With the dividend yield being not applicable, there is no payout ratio to consider. The company's gross margin stands at 100.0%, but this may be skewed due to its significant net loss.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About Lyell Immunopharma, Inc.
Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The company develops therapies using various approaches, such as c-Jun overexpression and NR4A3 gene knockout, to endow functional resistance to exhaustion; Epi-R to generate population of stem-like T cells with reduced exhaustion and improved proliferation and antitumor activity; CD62L positive enrichment to generate CAR T cells with enhanced antitumor activity; and Stim-R, a proprietary synthetic-cell mimetic. It is also developing IMPT-314, a dual-targeting CD19/CD20 CAR T-cell product candidate that is in Phase 1/2 clinical development for the treatment of patients with aggressive relapsed/refractory large B-cell non-Hodgkin lymphoma; and solid tumors program which is in preclinical trial targeting solid tumor indications. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
Visit website →Key Statistics
- Market Cap
- $595.04M
- P/E Ratio
- N/A
- 52-Week High
- $45.00
- 52-Week Low
- $7.65
- Avg Volume
- 62.96K
- Beta
- -0.14
Company Info
- Industry
- Biotechnology
- Exchange
- NMS
- Country
- United States
- Employees
- 300